Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316854 | 0.89 | PKM (0.44) | ACVR1ALDH1A1TDP1POLB | |
| SCHEMBL17289905 | 0.85 | GAA (0.40) | HTR6DRD2DRD3ALDH1A1 | |
| SCHEMBL29941106 | 0.84 | CA12 (0.42) | HTR6ALDH1A1 | |
| SCHEMBL17289842 | 0.84 | CA12 (0.42) | HTR6ALDH1A1 | |
| SCHEMBL4309099 | 0.83 | HTR6 (0.37) | HTR6DRD2DRD3HTR2BSMN1; SMN2 | |
| SCHEMBL26104341 | 0.82 | HTR6 (0.39) | HTR6DRD2DRD3HTR1AFGFR4 | |
| SCHEMBL30362017 | 0.82 | HTR6 (0.39) | HTR6DRD2DRD3HTR1AFGFR4 | |
| SCHEMBL17290071 | 0.82 | ABL1 (0.43) | ACVR1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4323609 | 0.81 | HTR1A (0.42) | HTR6DRD2HTR1AHTR7ALDH1A1 | |
| SCHEMBL4318163 | 0.81 | AURKA (0.40) | HTR6ACVR1NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
| US-10072001-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-3152210-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | HTR6 3840/4885DRD2 4868/4885DRD3 4865/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | HTR6 3840/4885DRD2 4868/4885DRD3 4865/4885 |
| US-10072001-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | HTR6 3840/4885DRD2 4868/4885DRD3 4865/4885 |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | HTR6 3840/4885DRD2 4868/4885DRD3 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.